Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Long-Term Debt Repayments (2020)

Anika Therapeutics (ANIK) has disclosed Long-Term Debt Repayments for 5 consecutive years, with $25.0 million as the latest value for Q4 2020.

  • On a quarterly basis, Long-Term Debt Repayments changed N/A to $25.0 million in Q4 2020 year-over-year; TTM through Dec 2021 was $50.0 million, a 0.0% change, with the full-year FY2020 number at $50.3 million, changed N/A from a year prior.
  • Long-Term Debt Repayments was $25.0 million for Q4 2020 at Anika Therapeutics, roughly flat from $25.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $25.0 million in Q3 2020 to a low of $25.0 million in Q4 2020.